Methods for generating structure-switching aptamers and uses thereof
US-11162960-B2 · Nov 2, 2021 · US
US11408850B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11408850-B2 |
| Application number | US-202117354342-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 22, 2021 |
| Priority date | Jun 22, 2020 |
| Publication date | Aug 9, 2022 |
| Grant date | Aug 9, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The subject invention provides materials and methods for single-step fluorescence and electrochemical detection of small molecules, e.g., fentanyl and its analogs, in a sample. The subjection invention provides nucleic acids materials, e.g., aptamers (nucleic acid oligonucleotides) that can bind to fentanyl and its analogs with nanomolar affinity and high specificity against illicit drugs, adulterants, and cutting agents commonly existing in seized samples. The method for detecting fentanyl and/or its analogs in a sample comprises contacting the sample with an aptamer-based sensor selective for fentanyl and its analogs, and sensitively, specifically, and rapidly detecting fentanyl and/or its analogs in the sample.
Opening claim text (preview).
We claim: 1. An aptamer-based sensor comprising one or more aptamers, each aptamer comprising the nucleic acid sequence selected from SEQ ID NO: 11 and sequences sharing at least 95% identity with SEQ ID No: 11, and optionally one or more aptamers selected from 5′-CTTACGAC(N30)GTCGTAAG-3′ (SEQ ID NO: 41) and 5′-TGGCAGAACTTACGAC(N30)GTCGTAAG-3′ (SEQ ID NO: 70), wherein N30 is selected from SEQ ID NOs: 42-69 and sequences sharing at least 95% identity with SEQ ID NOs: 42-69. 2. The aptamer-based sensor according to claim 1 , the one or more aptamers wherein at least one aptamer is modified by addition of a reporter label. 3. The aptamer-based sensor according to claim 2 , wherein the reporter label is a fluorescent dye, electroactive tag, a gold nanoparticle (AuNP), or a fluorescent molecule and quencher pair. 4. The aptamer-based sensor according to claim 1 , further comprising an aptamer comprising the nucleic acid sequence selected from SEQ ID NOs: 9-10, 17-19, 22-23, 28-30 and 32. 5. The aptamer-based sensor according to claim 1 , each aptamer having a maximal length of 73 nucleotides. 6. The aptamer-based sensor according to claim 1 , further comprising at least one aptamer selected from SEQ ID NOs: 6-36, and 83, and sequences sharing at least 95% identity with SEQ ID NOs: 6-36, and 83. 7. The aptamer-based sensor according to claim 1 , further comprising a modified or unmodified cDNA sequence selected from SEQ ID NOs: 2, 37, 73, 74, 75, 76, and 77. 8. A method for detecting fentanyl and/or an analog thereof in a sample comprising contacting the sample with the aptamer-based sensor of claim 1 , and detecting fentanyl and/or the analog thereof in the sample, the detection of fentanyl and/or the analog thereof comprising measuring a signal generated upon binding of fentanyl and/or the analog thereof to the aptamer-based sensor, wherein the signal is a change in absorbance change in fluorescence intensity, or change in electrochemical signal, the aptamer-based sensor further comprising a modified or unmodified cDNA sequence selected from SEQ ID NOs: 2, 37, 73, 74, 75, 76, and 77. 9. The method according to claim 8 , wherein the sample is a biological sample or an environmental sample. 10. The method according to claim 8 , wherein the biological sample is selected from blood, serum, plasma, urine, tears, and saliva. 11. The method according to claim 8 , wherein the analog is selected from Acetyl fentanyl, Furanyl fentanyl, Acrylfentanyl, Butyryl fentanyl, Valeryl fentanyl, Cyclopropyl fentanyl, Methoxyacetyl fentanyl, cis-3-methyl Fentanyl, p-methoxy Furanyl fentanyl, p-fluoro Fentanyl, p-methoxy Butyryl fentanyl, Remifentanil, alpha-methyl Thiofentanyl, o-methyl Furanyl fentanyl, and p-Fluoroisobutyryl fentanyl. 12. The method according to claim 8 , further comprising an aptamer comprising the nucleic acid sequence selected from SEQ ID NOs: 9-10, 17-19, 22-23, 28-30 and 32.
Marker; Tag · CPC title
Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53) · CPC title
being a redox reaction, e.g. detection by cyclic voltammetry (voltammetry per se G01N27/42, G01N27/48) · CPC title
in a process of directed evolution, e.g. SELEX, acquiring a new function · CPC title
Aptamers · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.